Filed by Xeris Pharmaceuticals, Inc.
pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: Strongbridge Biopharma plc
Commission File No.: 001-37569
Date: September 13, 2021
The following
communication is being filed in connection with the proposed acquisition of Strongbridge Biopharma plc (Strongbridge) by Xeris Pharmaceuticals, Inc. (Xeris)
Excerpts from the transcript of HC Wainwrights 23rd annual Global Investment Conference.
Michael Brotherton Good afternoon everyone and thank you for joining the HC Wainwright 23rd Annual Global Investment Conference.
Id like to introduce our next presenter. Id like to welcome Paul Edick, Chairman and CEO of Xeris Pharmaceuticals.
Paul Edick Thank you Michael. Appreciate the opportunity to be with you today to talk about Xeris.
And what are we becoming? I said at the outset that were becoming a biopharmaceutical company developing and commercializing unique therapies for patient
populations and endocrinology, neurology, and gastroenterology. Part of the journey is a recently announced acquisition of Strongbridge Biopharma, which at the end of the day, when combined with Xeris, will create an innovative leader in
endocrinology and rare diseases, in particular neuromuscular disease. The resulting company will have its first fight at increased revenue portfolio, specialized commercial platform in both neuromuscular disease and endocrinology, and eventually at
gastroenterology, and expanded development pipeline, which is in the form of the RECORLEV product which is in endocrinology which is currently in front of the FDA and has its approval date in early first quarter of next year. The combination will
create a strengthened strategic and financial profile with significant operating cash and we will realize significant synergies potentially up to $50 million worth of synergies by combining the two companies. So we are very quickly becoming a
larger, more diverse, stronger company in the biotechnology area.
We have a strong intellectual property estate, strong cash position, and experienced leadership team and with the close of the Strongbridge acquisition will be
a much stronger company with a much more diversified portfolio.
No Profit Forecast/Asset Valuations
No statement in this communication is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings
or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Strongbridge, Xeris or Xeris Biopharma Holdings, Inc. (being the entity under which Xeris and Strongbridge will be combined) as
appropriate. No statement in this communication constitutes an asset valuation.
Responsibility Statement Required by the Irish Takeover Panel Act,
1997, Takeover Rules 2013 (the Irish Takeover Rules)
The directors of Xeris accept responsibility for the information contained in this
communication. To the best of the knowledge and belief of the Xeris directors (who have taken all reasonable care to ensure that such is the case) the information contained in this communication is in accordance with the facts and does not omit
anything likely to affect the import of such information.